BRIVA - Overview: Brivaracetam, Plasma

Assessing compliance and toxicity for brivaracetam

CALNN - Overview: Calretinin Immunostain, Technical Component Only

Separating mesotheliomas from carcinomas which usually lack expression of calretinin

CLU - Overview: Chloride, 24 Hour, Urine

Indication of fluid balance and acid-base homeostasis using a 24-hour urine collection

APOA1 - Overview: Apolipoprotein A1, Serum

Evaluating risk for atherosclerotic cardiovascular disease Aiding in the detection of Tangier disease

AMIO - Overview: Amiodarone, Serum

Monitoring amiodarone therapy, especially when amiodarone is coadministered with other drugs that may interact Evaluating possible amiodarone toxicity Assessing patient compliance

AMPHM - Overview: Amphetamine-Type Stimulants Confirmation, Meconium

Detecting in utero exposure to amphetamine-type stimulants up to 5 months before birth

CRT2F - Overview: Creatinine, 24 Hour, Urine

Normalizing urinary analytes to account for the variation in urinary concentration

CLOM - Overview: Clomipramine, Serum

Determining whether a poor therapeutic response is attributable to noncompliance Monitoring serum concentration of clomipramine and norclomipramine to assist in optimizing the administered dose

HDCH - Overview: Cholesterol, High-Density Lipoprotein (HDL), Serum

Measurement of serum high-density lipoprotein concentrations for managing atherosclerotic cardiovascular disease risk

DSAC - Overview: Disaccharidase Activity Panel, Tissue

Evaluation of patients who present with signs or symptoms suggestive of disaccharidase disorders This test is not intended for carrier detection.